All In Biotech

Drug Trial Radar · NCT00500682

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,020 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,020

Actual

Start

Jul 2007

Primary completion

Oct 2011

Study completion Oct 2011

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
Collaborators
Kureha Corporation
First posted
Jul 13, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1\) To evaluate the effectiveness of AST-120 (spherical carbon adsorbent) added to standard-of-care therapy in moderate to severe Chronic Kidney Disease (CKD), on time to first occurrence of any event of the triple composite outcome of initiation of dialysis, kidney transplant or doubling of serum creatinine (sCr) when compared with placebo; 2) To evaluate the safety and tolerability of long-term AST-120 therapy in patients with CKD; 3) To evaluate the effects of AST-120 versus placebo, on other measures of renal function.

Conditions

  • Chronic Kidney Disease

Interventions

  • PlaceboDrug

    9g /day (3 times a day)

  • AST-120Drug

    9g /day (3 times a day)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of Dialysis Initiation, Kidney Transplantation, and Serum Creatinine Doubling. Number of Participants Meeting the Criteria Are Reported.Time frame: Beyond Week 48, a 12-week visit cycle continued until the end of the study or until individual patients reached an endpoint
  2. Number of Participants With Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse EventsTime frame: Approximately 42 months

Locations

105 sites in 12 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Alhambra, California

  • Site not named

    Covina, California

  • Site not named

    Glendale, California

  • Site not named

    Los Angeles, California

  • Site not named

    Stamford, Connecticut

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Hudson, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    Spring Hill, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Winter Park, Florida

  • Site not named

    Kansas City, Kansas

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Ypsilanti, Michigan

  • Site not named

    Kansas City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Camden, New Jersey

  • Site not named

    Eatontown, New Jersey

  • Site not named

    Port Washington, New York

  • Site not named

    Springfield Gardens, New York

  • Site not named

    Asheville, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Dayton, Ohio

  • Site not named

    Toledo, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Rock Hill, South Carolina

  • Site not named

    Nashville, Tennessee

  • Site not named

    Arlington, Texas

  • Site not named

    Dallas, Texas

  • Site not named

    Houston, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Appleton, Wisconsin

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.